← Scroll for more →
Financial Statements — TSEM
Balance Sheet
(in billions USD)| Metric | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|
| Cash & Equivalents | 0.32 | 0.21 | 0.22 |
| Short-term Investments | -- | -- | 0.19 |
| Accounts Receivable | 0.16 | 0.17 | 0.14 |
| Inventory | 0.33 | 0.25 | 0.21 |
| Total Current Assets | 1.44 | 1.32 | 1.12 |
| Property, Plant & Equipment | 1.02 | 0.88 | 0.86 |
| Total Non-current Assets* | 1.09 | 1.01 | 1.01 |
| Total Assets | 2.53 | 2.32 | 2.13 |
| Accounts Payable | 0.15 | 0.13 | 0.10 |
| Total Current Liabilities | 0.30 | 0.35 | 0.30 |
| Long-term Debt | 0.18 | 0.20 | 0.23 |
| Total Non-current Liabilities* | 0.22 | 0.29 | 0.31 |
| Total Liabilities | 0.52 | 0.64 | 0.61 |
| Total Stockholder Equity* | 2.01 | 1.71 | 1.52 |
← Scroll for more columns →
* Derived from reported values
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Total Revenue | 351.18 | 357.19 | 426.17 | 362.14 |
| Cost of Revenue | 264.26 | 270.67 | 313.73 | 288.38 |
| Gross Profit | 86.92 | 86.52 | 112.44 | 73.76 |
| Research & Development | 18.99 | 19.45 | 20.48 | 21.08 |
| Selling, General & Admin | 19.05 | 17.39 | 21.29 | 18.67 |
| Total Operating Expenses | 31.77 | 35.99 | 41.77 | 39.75 |
| Operating Income | 55.15 | 50.53 | 70.67 | 34.00 |
| Pretax Income | 62.86 | 54.45 | 62.51 | 33.52 |
| Tax Provision | 6.11 | 5.75 | 4.34 | 2.20 |
| Net Income | 53.45 | 51.19 | 58.08 | 30.87 |
| Basic EPS | 0.48 | 0.46 | 0.53 | 0.29 |
| Diluted EPS | 0.48 | 0.46 | 0.53 | 0.28 |
← Scroll for more columns →
Cash Flow Statement
(in millions USD)| Metric | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|
| Operating Cash Flow | 148.22 | 274.67 | 180.66 |
| Capital Expenditures | 194.68 | 130.22 | 105.60 |
| Free Cash Flow* | (46.46) | 144.45 | 75.06 |
| Investing Cash Flow | (127.87) | (224.96) | (124.26) |
| Financing Cash Flow | (36.96) | (38.71) | (48.78) |
← Scroll for more columns →
* Derived from reported values